Verona Pharma Plc (VRNA)

[Hoskuld]

If at $625m run rate by end of Q1 (current pace suggests this) and uptake continue at least at this pace, then Q2 would end with roughly the 64,000 patients it takes to get to a $1b run rate, and Q3 would end with $1.4b run rate, and Q4 would end with a $1.8b run rate. I think progress will be better the more I look at this, so let's say $2b run rate. That would make it possible - I mean just possible - that 2025 revenue could reach that $1b level. That would be ahead of schedule and point to the $5b-$10b revenue area that I think we are headed for (US market only.)